Emerging Markets Are Next Turn In Sanofi Consumer Health Growth
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Sanofi's consumer health sales were off 1%, at $1.4bn, during its latest quarter compared to a corresponding year-ago period, with inclusion of Boehringer's OTC drug and nutritional product brand revenues. But for Sanofi's legacy consumer products only, sales were up 42.5%.